India can bar drugmakers from future approvals over false data and mislabelled products
The health ministry has amended the Drugs Rules, 1945, enabling central and state licensing authorities to debar manufacturers that submit fraudulent approval data or mislabel products. Action will follow a show-cause process, with an appeal mechanism available.
India’s health ministry has amended Drugs Rules, 1945, allowing state or central licensing authorities to bar drugmakers from future applications for submitting false approval data or mislabelling products, following a show-cause process and with an appeal mechanism.
Why this matters
No related recent signals were provided. The rule change adds enforcement risk for drug manufacturers as scrutiny of retail-company operations accelerates.
retail-company is accelerating, up 167000% QoQ.